Richard A. Lake

35 Stirling Highway
Crawley, WA 6009, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.

Journal: Scientific reports
Published: November 03, 2025

Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients.

Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients.

Journal: Oxford open immunology
Published: December 10, 2024

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.

Journal: Oncoimmunology
Published: April 30, 2024

Mesothelioma survival prediction based on a six-gene transcriptomic signature.

Mesothelioma survival prediction based on a six-gene transcriptomic signature.

Journal: iScience
Published: March 14, 2024

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.

Journal: Frontiers in toxicology
Published: January 19, 2024

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Journal: Cell reports. Medicine
Published: December 26, 2023

Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner.

Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner.

Journal: BMC cancer
Published: August 18, 2023

Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy.

Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy.

Journal: Scientific data
Published: June 20, 2023

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.

Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.

Journal: PloS one
Published: September 11, 2022

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action.

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action.

Journal: Frontiers in oncology
Published: June 02, 2022

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.

Journal: Frontiers in immunology
Published: February 09, 2022

Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.

Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.

Journal: Frontiers in oncology
Published: January 06, 2022
Showing 1-12 of 67

Last Updated: 09/26/2026